In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...
The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
Dry eye disease (DED) is a common disorder affecting hundreds of millions of people around the world. The disease is characterized by eye discomfort, visual impairment, tear film instability, and ...
Introduction Age-related macular degeneration (AMD) is a prevalent eye disease among middle-aged and older adults. AMD leaves the patient with irreversible deteriorating vision, which profoundly ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
Optometrist Amy Green discussed the importance of OCT in identifying AMD cases during the AOP’s Locum Clinical Skills ...
A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback